Qiagen stock pre-market at EUR 40.82: plus 0.15 percent

Qiagen stock was at EUR 40.82 pre-market on October 6, 2026, up 0.15 percent versus the prior Lang & Schwarz close. QIAGEN also reported FDA clearance for a new test panel.

Qiagen stock was at EUR 40.82 pre-market on October 6, 2026, at 8:51 a.m. CEST, up 0.15 percent versus the EUR 40.76 Lang & Schwarz close on October 5.

Qiagen pre-market price

Lang & Schwarz recorded a bid of EUR 40.72 and an ask of EUR 40.91 at 8:51 a.m. CEST on October 6, 2026. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Qiagen stock.

FDA clearance expands QIAstat-Dx portfolio

In a September 28, 2026, press release, QIAGEN said U.S. laboratories had access to its complete QIAstat-Dx bloodstream infection portfolio after the U.S. Food and Drug Administration cleared the BCID GN Plus AMR Panel. The panel identifies 13 gram-negative bacterial targets and 18 antimicrobial resistance markers in about one hour.

QIAGEN said the new panel complements its previously cleared gram-positive and fungal panel. Together, the two panels cover 33 pathogen targets and 28 antibiotic resistance markers.